1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided pediatric AML treatment. 2.High-risk patients identified by MRD guidance ...
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...
1. Oral azacytidine also known as CC-486 has been found to improve survival outcomes in patients with acute myeloid leukemia. ...
Image: PD 1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid ...
Image: PD AML 1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell ...
